New targeted drug holds promise for tough liver cancer
Disease control
Not yet recruiting
This study tests a new drug called BB102 for people with advanced liver cancer that has not responded to other treatments. The drug targets a specific protein (FGF19) found in some liver cancers. About 60 adults will take part to see if the drug can shrink tumors and how safe it …
Phase: PHASE2 • Sponsor: Broadenbio Ltd., Co. • Aim: Disease control
Last updated May 02, 2026 07:52 UTC